Cost-effectiveness analysis of routine immunization and supplementary immunization activity for measles in a health district of Benin

Cost Effectiveness and Resource Allocation

Pierre Levy¹  Landry Kaucley² 

[1] Paris Dauphine University, LEDa-LEGOS, Place du Marechal de Lattre de Tassigny, Paris, 75016, France;Health District of Natitingou, Ministry of Health, Natitingou, Benin

关键词: Benin;    Routine immunization;    Supplementary immunization activity;    Efficiency;    Measles;   

Others  :  1224078
DOI  :  10.1186/s12962-015-0039-7

 received in 2014-12-11, accepted in 2015-08-10,  发布年份 2015

【 摘 要 】

Background

This study was carried out at district level to describe the cost structure and measure the effectiveness of delivering supplementary immunization activity (SIA) and routine immunization (RI) for measles in Benin, a country heavily affected by this disease.

Methods

This cost-effectiveness study was cross sectional and considered 1-year time horizon. RI consists to vaccinate an annual cohort of children aged 0–1 year old and SIA consists to provide a second dose of measles vaccine to children aged 0–5 years old in order to reach both those who did not seroconvert and who were not vaccinated through RI. Ingredients approach to costing was used. Effectiveness indicators included measles vaccine doses used, vaccinated children, measles cases averted and disability adjusted life years averted. Data were collected from all the 18 health care centers of the health district of Natitingou for the year 2011. In the analysis, the coverage was 89 % for RI and 104 % for SIA.

Results

SIA total cost was higher than RI total cost (15,796,560 FCFA versus 9,851,938 FCFA). Personnel and vaccines were the most important cost components for the two strategies. Fuel for cold chain took a non-negligible part of RI total cost (4.03 %) because 83 % of refrigerators were working with kerosene. Cost structures were disproportionate as social mobilization and trainings were not financed during RI contrarily to SIA. In comparison with no intervention, the two strategies combined permitted to avoid 12,671 measles cases or 19,023 DALYs. The benefit of SIA was 5601 measles cases averted and 6955 additional DALYs averted. Cost per vaccinated child for SIA (442 FCFA) was lower than for RI (1242 FCFA), in line with previous data from the literature. Cost per DALY averted was 2271 FCFA (4.73 USD) for SIA and 769 FCFA (1.60 USD) for RI. Analysis showed that low vaccine efficacy decreased the cost-effectiveness ratios for the two strategies. SIA was more cost-effective when the proportion of previously unvaccinated children was higher. For the two strategies, costs per DALY were more likely to vary with measles case fatality ratio.

Conclusions

SIA is costlier than RI. Both SIA and RI for measles are cost-effective interventions to improve health in Benin compared to no vaccination. Policy makers could make RI more efficient if sufficient funds were allocated to communications activities and to staff motivation (trainings, salaries).

【 授权许可】

   
2015 Kaucley and Levy.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

【 参考文献 】

• [1]World Health Organization: Le traitement de la rougeole chez l’enfant. WHO/EPI/LHIS/97.02
• [2]World Health Organization: Global measles and rubella strategic plan: 2012–2020
• [3]Ministère de la Santé: Annuaire statistique 2010. Bénin
• [4]Zone Sanitaire de Natitingou: Annuaire statistique 2010. Bénin
• [5]Sossou AR. Rapport mensuel de surveillance intégrée. OMS, Bureau Pays Bénin, Juillet; 2011.
• [6]World Health Organization: PQS device catalogue. WHO/IVD/11.08. November 2012
• [7]Measles vaccines: WHO position paper. Wkly Epidemiolog Rec. 2009; 84:349-360.
• [8]Murray CJL, Salomon JA, Mathers CD, Lopez AD (eds) (2002) Summary measures of population health: concepts, ethics, measurement and application. WHO, Geneva. http://www.who.int/pub/smph/en/index.htlm. Accessed 9 Feb 2011
• [9]Murray CJL. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994; 72(3):429-445.
• [10]Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int J Epidemiol. 2009; 38:192-205.
• [11]Sudfield CR, Halsey NA. Measles Case Fatality ratio in India; a review of community based studies. Indian Pediatr. 2009; 46:983-989.
• [12]Life table for WHO member states, Africa report, 2007. WHO, Geneva; 2007.
• [13]Centers for Disease Control and Prevention (2004) Epidemiology and Prevention of Vaccine-Preventable Diseases, 8th edn. Measles, Chapter 10. http://www.cdc.gov/vaccines/pubs/pinkbook/default.htm. Accessed 1 June 2013
• [14]World Health Organization (2008) The global burden of disease: 2004 update. WHO, Geneva. http://www.who.int/evidence/bod. Accessed 9 Feb 2011
• [15]Médecins Sans Frontières: Epidémie de rougeole au Sud Kivu (RDC): Enquête de couverture vaccinale. Rapport final. Avril 2011
• [16]Van den Ent M, Gupta SK, Hoekstra E. Two doses of measles vaccines reduce measles deaths. Indian Pediatr. 2009; 46:933-938.
• [17]Manzo ML (2003) Etude de l’efficience de la campagne de vaccination anti-rougeoleuse réalisée dans le district sanitaire de Niamey commune II en décembre 2004. Mémoire du DIU “organisation et management des systèmes publics de vaccination dans les pays en développement”, Université de Paris Dauphine et Université de Cocody Abidjan, 2003. http://www.epivacplus.org/scientific_articles. Accessed 15 Feb 2013
• [18]Traore B (2003) Etude comparative des JNV Polio dans la région de Tombouctou de 2000–2002. Mémoire du DIU “organisation et management des systèmes publics de vaccination dans les pays en développement”, Université de Paris Dauphine et Université de Cocody Abidjan. http://www.epivacplus.org/scientific_articles. Accessed 15 Feb 2013
• [19]Gning B (2007) Etude des coûts et financement de la campagne de rattrapage contre la rougeole dans le district sanitaire de Fatick (Sénégal), octobre 2006. Mémoire du DIU “organisation et management des systèmes publics de vaccination dans les pays en développement”, Université de Paris Dauphine et Université de Cocody Abidjan. http://www.epivacplus.org/scientific_articles. Accessed 15 Feb 2013
• [20]Varwa AO (2006) Analyse des coûts des journées nationales de vaccination polio en 2004 et 2005 en Mauritanie. Mémoire du DIU “organisation et management des systèmes publics de vaccination dans les pays en développement”, Université de Paris Dauphine et Université de Cocody Abidjan. http://www.epivacplus.org/scientific_articles. Accessed 15 Feb 2013
• [21]Ebong CE, Levy P. Impact of the introduction of new vaccines and vaccine wastage rate on the cost effectiveness of routine EPI: lessons learned from a descriptive study in a Cameroonian health district. Cost Eff Resour Alloc. 2011; 9:9. BioMed Central Full Text
• [22]Vijayaraghavan M, Martin RM, Sangrujee N, Kimani GN, Oyombe S, Kalu A et al.. Measles supplemental immunization activities improve measles vaccines coverage and equity: Evidence from Kenya, 2002. Health Policy. 2007; 83:27-39.
• [23]Dabral M. Cost-effectiveness of Supplementary Immunization for Measles in India. Indian Pediatr. 2009; 46:957-962.
• [24]Bishai D, Johns B, Nair D, Nabyonga-Orem J, Fiona-Makmot B, Simons E et al.. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda. J Infect Dis. 2011; 204 Suppl 1:S107-S115.
• [25]Ziao A (2006) Analyse des coûts des journées nationales de vaccination contre la poliomyélite dans un contexte de crise de la Côte d’Ivoire (Fév.-Mars 2004). Mémoire du DIU “organisation et management des systèmes publics de vaccination dans les pays en développement”, Université de Paris Dauphine et Université de Cocody Abidjan. http://www.epivacplus.org/scientific_articles. Accessed 15 Feb 2013
• [26]Edejer TT, Aikins M, Black R, Wolfson L, Hutubessy R, Evans DB. Cost effectiveness analysis of strategies for child health in developing countries. BMJ. 2005; 331(7526):1177.
• [27]Murray CJL, Ezzati M, Flaxman D et al.. GBD 2010: design, definitions and metrics. Lancet. 2012; 380:2063-2066.